System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Jin-Yuan Shih is an expert in Oncology at National Taiwan University Hospital (Taiwan). As of October 2026, ScienceLeadR ranks Jin-Yuan Shih in the top 1% of experts worldwide for EGFR mutation, Lung Neoplasms and Thoracic Neoplasms. Jin-Yuan Shih has authored 366 publications, the most recent in 2026, and is an investigator in 13 clinical trials, 4 of them ongoing. SLR score: 1,424 (community average: 125). How the SLR is computed.

LeadR Profile

Jin-Yuan Shih National Taiwan University Hospital Taiwan
1 424 ScienceLeadR Reputation 1424

Unlock

Register Login
Network Map

Oncology

Subspecialties: Pulmonology - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1991 - 2026
Source: PubMed

National Taiwan University Hospital

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 366

Citations

Citations: 20 979 1st author: 21 Last author: 92 Unique author: 1

Main journals

J Thorac Oncol 38
Lung Cancer 23
J Clin Oncol 20
J Formos Med Assoc 20
Cancer Res 14

Best Journals

J Clin Oncol 9
Ann Oncol 6
N Engl J Med 4

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Amivantamab plus chemotherapy vs. chemotherapy in participants with EGFR-mutant advanced non-small cell lung cancer after progression on osimertinib: a MARIPOSA-2 analysis of the Asian subgroup.
PMID 42870814 — cells, lung, safety, neoplasms, carcinoma, non-small-cell lung, drug therapy, lung neoplasms, small cell lung carcinoma, response evaluation criteria in solid tumors, chemotherapy		Transl Lung Cancer Res20260
Response to comments on "Effectiveness of amivantamab compared with real-world therapies in patients with non-small cell lung cancer with EGFR exon 20 insertion mutations post platinum-based chemotherapy".
PMID 42362429 — cells, lung, neoplasms, carcinoma, non-small-cell lung, drug therapy, exons, lung neoplasms, small cell lung carcinoma, therapeutics, mutation, chemotherapy		J Formos Med Assoc20260
Few-Shot Lung Cancer Classification via Electronic Nose Using Large Language Models: A Multicentre Prospective Study.
PMID 42167356 — language, lung, respiratory tract diseases, neoplasms, classification, electronic nose, lung neoplasms, diagnosis, nose, prospective studies		Respirology20260
Correction: Real-World Outcomes of Sequential Afatinib and Osimertinib Versus Afatinib and Chemotherapy in EGFR-Mutant NSCLC: Taiwan Multicenter GIANT Study.
PMID 42056681 — neoplasms, carcinoma, non-small-cell lung, drug therapy, afatinib, chemotherapy		Target Oncol20260
Stanniocalcin 2-Induced Autophagy Confers Resistance of Lung Cancer Cells to EGFR Inhibition via the ERK/Beclin 1 Signaling.
PMID 42043462 — cells, lung, autophagy, rna, small interfering, neoplasms, lung neoplasms, beclin-1, vacuoles		Cancer Med20260

Clinical Studies 13

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1 Study Chair: 1

By phase:

Phase 3 6
N/A 5
Phase 2 1
Phase 2/Phase 3 1

By status:

Active not recruiting 7
Completed 3
Recruiting 2
Unknown 1

By type:

Interventional 8
Observational 5

By Monocentric/Multicentric:

monocentric 2
multicentric2to4 1
multicentric5to9 1
multicentricup10 9

Main Topics

Ongoing Clinical Trials

4 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Retrospective Observational Study of Nivolumab in Combination With Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC Patients Real World Experience in Taiwan (NEOREAL)
NCT07169708 — cells, lung, neoplasms, carcinoma, non-small-cell lung, drug therapy, lung neoplasms, small cell lung carcinoma, neoadjuvant therapy, nivolumab, therapeutics, chemotherapy		N/ARecruiting2026
A Pan Asian Clinical Database of EGFR Exon 20 Insertion Mutated NSCLC
NCT06418412 — cells, epidemiology, lung, neoplasms, carcinoma, non-small-cell lung, exons, lung neoplasms, small cell lung carcinoma, carcinoma		N/ARecruiting2024
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
NCT05740566 — cells, lung, neoplasms, drug therapy, lung neoplasms, small cell lung carcinoma, topotecan, chemotherapy, carcinoma		Phase 3Active not recruiting2023
A Study of Amivantamab and Lazertinib in Combination With Platinum Based Chemotherapy Compared With Platinum Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR) Mutated Locally Advanced or Metastatic Non Small Cell Lung Cancer After Osimertinib Failure
NCT04988295 — cells, epidermal growth factor, pemetrexed, lung, growth, neoplasms, carcinoma, non-small-cell lung, drug therapy, lung neoplasms, receptors, growth factor, small cell lung carcinoma, carboplatin, chemotherapy, carcinoma		Phase 3Active not recruiting2021

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS